Day One Biopharmaceuticals, Inc. financial statements, including revenue, expenses, and profit
The total revenue of DAWN for the last quarter is 29.21 M USD, and it's 68.85% lower compared to the previous quarter. The net income of Q4 24 is -65.71 M USD.